Dublin, Ireland, January 4, 2017 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that its Chief Executive Officer, Darren Cunningham, will deliver a corporate presentation at the 9th Annual Biotech Showcase™, being held January 9-11, 2017 at the Hilton San Francisco Union Square in San Francisco.
Mr. Cunningham will present an overview of the Company and discuss its development and business strategy on Tuesday, January 10th, at 4:15pm (PST) in Room 1. Mr. Cunningham will be available for questions immediately following the presentation. Members of the investment community who are interested in meeting with management during the conference are encouraged to contact the company (contact details below) to schedule a meeting.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com
For Further Information Contact:
Darren Cunningham, Chief Executive Officer
Inflection Biosciences Ltd
+353 (0)1 4003615